Lista de obras - Bob T Li - Dominio Público Uruguay

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

artículo científico publicado en 2017

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

artículo científico publicado en 2015

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

artículo científico publicado en 2017

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

scientific article published on 12 July 2019

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

scientific article published on 11 February 2020

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

artículo científico publicado en 2021

Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma

artículo científico publicado en 2015

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

scientific article published on 19 May 2020

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

artículo científico publicado en 2018

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas

scientific article published on 01 July 2019

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

artículo científico publicado en 2015

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

artículo científico publicado en 2015

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

artículo científico publicado en 2020

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

scientific article published on 25 November 2019

Localized malignant pleural mesothelioma with renal metastasis

artículo científico publicado en 2015

MET exon 14-altered lung cancers and MET inhibitor resistance

artículo científico publicado en 2020

Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy

artículo científico publicado en 2014

Measurement of preoperative lobar lung function with computed tomography ventilation imaging: progress towards rapid stratification of lung cancer lobectomy patients with abnormal lung function.

artículo científico publicado en 2015

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

artículo científico publicado en 2016

Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib

artículo científico publicado en 2020

PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer.

artículo científico publicado en 2016

Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report.

artículo científico publicado en 2015

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

artículo científico publicado en 2019

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

artículo científico publicado en 2016

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

artículo científico publicado en 2016

Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors

artículo científico publicado en 2016

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

artículo científico publicado en 2015

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

scientific article published on 25 March 2020

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials

artículo científico publicado en 2016

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

artículo científico

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice

artículo científico publicado en 2014

What does the future hold for immunotherapy in cancer?

artículo científico publicado en 2016

Lista de obras de Bob T Li

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

Localized malignant pleural mesothelioma with renal metastasis

MET exon 14-altered lung cancers and MET inhibitor resistance

Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy

Measurement of preoperative lobar lung function with computed tomography ventilation imaging: progress towards rapid stratification of lung cancer lobectomy patients with abnormal lung function.

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib

PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer.

Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report.

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice

What does the future hold for immunotherapy in cancer?